WSLHD doctors honoured in the Clarivate Highly Cited Researchers List

Western Sydney Local Health District’s (WSLHD) Professor Jacob George and Dr Matteo Carlino have been recognised in the highly anticipated “Highly Cited Researchers” list by Clarivate.

Professor Jacob George is an accomplished clinical scientist in the field of liver cancer research as well as translational and basic research on people with liver disease and liver cancer.  He also undertakes clinical care of patients with liver disease.

Dr Matteo Carlino specialises as a medical oncologist, focusing on both clinical practice and academic pursuits related to melanoma and complex skin cancer.

The Clarivate list identifies researchers whose scholarly work has had a significant and lasting impact on their respective fields, which is measured by the number of citations a research study has received.

The substantial number of citations reflects widespread recognition and frequent referencing of Professor Jacob George and Dr Matteo Carlino’s research contributions by their peers.

This underscores the instrumental role their findings and insights have played in shaping ongoing research and fostering discussions within their respective areas of expertise.

The Pulse interviewed Professor Jacob George and Dr Matteo Carlino, here are their thoughts on achieving this honour.

Q&A with Professor Jacob George, Head, Department of Gastroenterology and Hepatology:

How does it feel to be recognised on the 2023 Clarivate Highly Cited Researchers list?

It is really about recognition of the whole team that contributes to the work rather than an accolade for an individual. Without a great team, there would not be an accolade.

Can you share a key finding or breakthrough from your research that you are particularly proud of?

We have recently discovered predictors of response to immune-based therapies for liver cancer. They predict who will have more aggressive liver cancer and who will respond best to treatment with immune-based drugs. We are very hopeful that this can be translated to improve patient lives and care in the not-too-distant future.

In what ways do you see your research impacting healthcare practices or patient outcomes?

The research we do underpins and ensure that people with disease receive the most up to date, effective and best treatment for whatever condition they have.

What are your future research goals or areas you would like to explore further?

My goal is to embed the next generation of researchers (both clinical, translational and basic researchers) into the fabric of our LHD. Only through research can we hope to improve the lives of the people who come to us for treatment.

WSLHD has been a great springboard for my research and will continue to fulfill that role in future given the many patients that we see and help on a daily basis.

Professor Jacob George
Q&A with Dr Matteo Carlino, Blacktown and Westmead Hospitals, Head of Department of Medical Oncology:

How does it feel to be recognised on the 2023 Clarivate Highly Cited Researchers list?

I am honoured to be included in the list as a representative of the oncology department and Melanoma multidisciplinary team in recognition of our contribution to the development of melanoma therapies.

Can you share a key finding or breakthrough from your research that you are particularly proud of?

I am most proud of our involvement in the development of a number of therapies which have revolutionised the treatment of melanoma and other malignancies. I am particularly proud that Westmead/Blacktown’s involvement in these research endeavours has meant the patients of Western Sydney have had access to treatments years early than they otherwise would have.

In what ways do you see your research impacting healthcare practices or patient outcomes?

The therapies we have been involved in the development of have improved the survival of 100s of our patients over the years and 1000s around the country. Our translational research continues to improve our ability to select the correct treatment for individual patients.

What are your future research goals or areas you would like to explore further?

We are hoping to expand our clinical trials program into the use of cell therapy into melanoma and other solid tumours. These therapies are now standard for haematological malignancies and showing promise in other cancers, in conjunction with Westmead’s world leading haematology cell therapy service we hope to follow their lead into this exciting field.

Clinical research is a team effort. I am very grateful to my colleagues, medical, nursing, clinical trials, pharmacy and particularly our patients and their families who bravely enrol on clinical trials.

Dr Matteo Carlino